Skip to main content
SpringerLink
Log in

Monitoring effectiveness of medical therapy in 2006

  • Editorial point of view
  • Published:
Journal of Nuclear Cardiology Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pancholy SB, Fattah AA, Kamal AM, Ghods M, Heo J, Iskandrian AS. Independent and incremental prognostic value of exercise thallium single-photon emission computed tomographic imaging in women. J Nucl Cardiol 1995;2(Pt 1):110–6.

    PubMed  CAS  Google Scholar 

  2. Iskandrian AS, Chae SC, Heo J, Stanberry CD, Wasserleben V, Cave V. Independent and incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium imaging in coronary artery disease. J Am Coll Cardiol 1993;22: 665–70.

    Article  PubMed  CAS  Google Scholar 

  3. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging: a diagnostic tool comes of age. Circulation 1991;83:363–81.

    PubMed  CAS  Google Scholar 

  4. Shaw LJ, Hachamovitch R, Berman DS, Marwick TH, Lauer MS, Heller GV, et al. The economic consequences of available diag-nostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheter-ization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study Group. J Am Coll Cardiol 1999;33:661–9.

    Article  PubMed  CAS  Google Scholar 

  5. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657–71.

    PubMed  CAS  Google Scholar 

  6. Nissen SE, De Franco AC. Coronary intravascular ultrasound: implications for understanding the development and potential regression of atherosclerosis. Am J Cardiol 2001;88(Suppl 1):7–20.

    Google Scholar 

  7. Gould KL, Nakagawa Y, Nakagawa K, Sdringola S, Hess MJ, Haynie M, et al. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base-to-apex myocardial perfusion abnormal-ities by noninvasive positron emission tomography. Circulation 2000;101:1931–9.

    PubMed  CAS  Google Scholar 

  8. Blumenthal RS, Becker DM, Yanek LR, Aversano TR, Moy TF, Kral BG, et al. Detecting occult coronary disease in a high-risk asymptomatic population. Circulation 2003;107:702–7.

    Article  PubMed  Google Scholar 

  9. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899–906.

    PubMed  CAS  Google Scholar 

  10. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900–6.

    Article  PubMed  Google Scholar 

  11. Cerqueira M, Udelson J. Seventh Nuclear Cardiology Invitational Conference, Park City, Utah, 2004. J Nucl Cardiol 2005;12:480–509.

    Article  Google Scholar 

  12. Wackers FJTh, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al; Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymp-tomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27:1954–61.

    Article  PubMed  Google Scholar 

  13. Blumenthal RS, Becker DM, Moy TF, Coresh J, Wilder LB, Becker LC. Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. Circulation 1996;93:915–23.

    PubMed  CAS  Google Scholar 

  14. Sdringola S, Patel D, Gould KL. High prevalence of myocardial perfusion abnormalities on positron emission tomography in asymptomatic persons with a parent or sibling with coronary artery disease. Circulation 2001;103:496–501.

    PubMed  CAS  Google Scholar 

  15. Pitkanen OP, Raitakari OT, Rönnemaa T, Niinikoski H, Nuutila P, Iida H, et al. Influence of cardiovascular risk status on coronary flow reserve in healthy young men. Am J Cardiol 1997;79:1690–2.

    Article  PubMed  CAS  Google Scholar 

  16. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491–7.

    PubMed  CAS  Google Scholar 

  17. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530–8.

    PubMed  CAS  Google Scholar 

  18. Gould KL, Ornish D, Scherwitz L, Brown S, Edens RP, Hess MJ, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 1995;274:894–901.

    Article  PubMed  CAS  Google Scholar 

  19. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481–7.

    Article  PubMed  CAS  Google Scholar 

  20. Mostaza JM, Gomez MV, Gallardo F, Salazar ML, Martin-Jadraque R, Plaza-Celemin L, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000;35:76–82.

    Article  PubMed  CAS  Google Scholar 

  21. Schwartz RG, Pearson TA, Kalaria VG, Mackin ML, Williford DJ, Awasthi A, et al. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. J Am Coll Cardiol 2003; 42:600–10.

    Article  PubMed  CAS  Google Scholar 

  22. Morbidity & mortality: 2004 chart book on cardiovascular, lung, and blood diseases. Bethesda (MD): National Heart, Lung, and Blood Institute; 2004.

  23. Dakik HA, Kleiman NS, Farmer JA, He ZX, Wendt JA, Pratt CM, et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction. Circulation 1998;98:2017–23.

    PubMed  CAS  Google Scholar 

  24. Itti E, Klein G, Rosso J, Evangelista E, Monin JL, Gueret P, et al. Assessment of myocardial reperfusion after myocardial infarction using automatic 3-dimensional quantification and template matching. J Nucl Med 2004;45:1981–8.

    PubMed  Google Scholar 

  25. Ridker PM. Clinical application of C-reactive protein for cardio-vascular disease detection and prevention. Circulation 2003;107: 363–9.

    Article  PubMed  Google Scholar 

  26. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):S1-S9.

    Article  PubMed  CAS  Google Scholar 

  27. Mahmarian JJ, Shaw LJ, Olszlewski GH, Pounds BK, Frias ME, Pratt CM; INSPIRE Investigators. Adenosine sestamibi SPECT post-infarction evaluation (INSPIRE) trial: a randomized, prospective multicenter trial evaluating the role of adenosine Tc-99m sestamibi SPECT for assessing risk and therapeutic outcomes in survivors of acute myocardial infarction. J Nucl Cardiol 2004;11: 458–69.

    Article  PubMed  Google Scholar 

  28. Mahmarian JJ. Risk stratification post myocardial infarction: implications from the INSPIRE trial. Available from: URL: http://www.cardiologyonline.com/wchd05/abstracts/3093% 20Mahmarian.doc Accessed on November 22, 2005.

  29. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investiga-tors. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879–87.

    Article  PubMed  CAS  Google Scholar 

  30. Sdringola S, Nakagawa K, Nakagawa Y, Yusuf SW, Boccalandro F, Mullani N, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterollowering drugs in coronary artery disease. J Am Coll Cardiol 2003;41:263–72.

    Article  PubMed  CAS  Google Scholar 

  31. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 1998;98:1291–6.

    PubMed  CAS  Google Scholar 

  32. Kudes MA. Comparison of lipid and scintigraphic responses accompanying statin therapy: SPECT pravastatin CAD regression study [abstract]. J Nucl Cardiol 2005;12:S40.

    Article  Google Scholar 

  33. Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999;99:475–81.

    PubMed  CAS  Google Scholar 

  34. Kunnas TA, Lehtimaki T, Laaksonen R, Ilveskoski E, Janatuinen T, Vesalainen R, et al. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J Mol Med 2002;80:802–7.

    Article  PubMed  CAS  Google Scholar 

  35. Merhige ME, Watson GM, Oliverio JG, Shelton V, Frank SN, Perna AF. Efficacy of lipid lowering therapy in inducing arrest or reversal of coronary disease: serial assessment of perfusion with PET predicts clinical outcome [abstract]. J Nucl Cardiol 2004;11: S32.

    Article  Google Scholar 

  36. Grundy SM, Cleeman JI, Merz NB, Brewer HB Jr, Clark LT, Hunninghake DB, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.

    Article  PubMed  Google Scholar 

  37. Berman DS, Kang X, Schisterman EF, Gerlach J, Kavanagh PB, Areeda JS, et al. Serial changes on quantitative myocardial perfusion SPECT in patients undergoing revascularization or conservative therapy. J Nucl Cardiol 2001;8:428–37.

    Article  PubMed  CAS  Google Scholar 

  38. de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et al; Invasive versus Conservative Treat-ment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005;353:1095–104.

    Article  PubMed  Google Scholar 

  39. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44–51.

    PubMed  CAS  Google Scholar 

  40. Sharir T, Germano G, Kavanagh PB, Lai S, Cohen I, Lewin HC, et al. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. Circulation 1999;100: 1035–42.

    PubMed  CAS  Google Scholar 

  41. Romero-Farina G, Candell-Riera J, Aguadé-Bruix SS, De Leon G, Caresia AP, Mila-Lopez M, et al. Evolution of left ventricular systolic function after coronary revascularization and medical treatment in patients with ischemic cardiomyopathy [abstract]. J Nucl Cardiol 2005;12:S33.

    Google Scholar 

  42. Desideri A, Cortigiani L, Christen AI, Coscarelli S, Gregori D, Zanco P, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2005;46:1264–9.

    Article  PubMed  Google Scholar 

  43. Brindis RG, Douglas PS, Hendel RC, Peterson ED, Wolk MJ, Allen JM, et al; American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group; American Society of Nuclear Cardiology; American Heart Association. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfu-sion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Soci-ety of Nuclear Cardiology endorsed by the American Heart Association. J Am Coll Cardiol 2005;46:1587–605.

    Article  PubMed  Google Scholar 

  44. Berman DS, Wong ND, Gransar H, Miranda-Peats R, Dahlbeck J, Hayes SW, et al. Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. J Am Coll Cardiol 2004;44:923–30.

    Article  PubMed  CAS  Google Scholar 

  45. Des Prez RD, Gillespie RL, Jaber WA, Jaber WA, Noble GL, Soman P, et al. Cost-effectiveness of myocardial perfusion imaging: a summary of the currently available literature. J Nucl Cardiol 2005;12:750–9.

    Article  PubMed  Google Scholar 

  46. Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation 2002;105:32–40.

    Article  PubMed  Google Scholar 

  47. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;327:586–91.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, and the Division of Nuclear Medicine, Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY

    Ronald G. Schwartz & Mark A. Kudes

Authors
  1. Ronald G. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark A. Kudes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartz, R.G., Kudes, M.A. Monitoring effectiveness of medical therapy in 2006. J Nucl Cardiol 13, 184–190 (2006). https://doi.org/10.1007/BF02971242

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02971242

Search

Navigation